Arcutis Biotherapeutics, Inc. ARQT Operating lease liabilities
Operating lease liabilities at other companies
Other financials
Where this comes from
Reported directly by Arcutis Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept arqt:IncreaseDecreaseInOperatingLeaseLiabilities.
The official record: Arcutis Biotherapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arcutis Biotherapeutics, Inc.'s operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arcutis Biotherapeutics, Inc.'s operating lease liabilities?
- Arcutis Biotherapeutics, Inc. (ARQT) reported operating lease liabilities of -$137K in Q1 2026.
- How has Arcutis Biotherapeutics, Inc.'s operating lease liabilities changed year-over-year?
- Arcutis Biotherapeutics, Inc.'s operating lease liabilities increased by 31.5% year-over-year, from -$200K to -$137K.
- What is the long-term trend for Arcutis Biotherapeutics, Inc.'s operating lease liabilities?
- Over 4 years (2021 to 2025), Arcutis Biotherapeutics, Inc.'s operating lease liabilities has grown at a 26.4% compound annual growth rate (CAGR), from $266K to -$680K.
- What does operating lease liabilities mean?
- Measures the net change in obligations arising from operating lease agreements during the reporting period. This reflects the cash impact of lease payments made to lessors and the recognition of new lease obligations. Monitoring this helps investors understand the company's ongoing commitment to fixed rental costs and its impact on operating cash flow.